Form 4: ANI Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Muthusamy Shanmugam, Head of R&D and COO-Novitium Operations at ANI Pharmaceuticals, sold 2,743 shares of common stock at a weighted average price of $62, according to a Form 4 filing.

Summary

• Muthusamy Shanmugam, a Director and Officer (Head of R&D, COO-Novitium Ops) of ANI Pharmaceuticals Inc. (ANIP), reported a transaction involving the sale of company stock.
• On July 18, 2024, Shanmugam sold 2,743 shares of common stock at a weighted average price of $62.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2023.
• Following the transaction, Shanmugam directly owns 68,652 shares of ANI Pharmaceuticals.
• Shanmugam also indirectly owns 632,620 shares through Esjay LLC and 5,000 shares through SS Pharma LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-existing trading plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Executive stock sales are common and can be for various reasons, including diversification or personal financial planning. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on current inside information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates